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A basic tenet of antibody-based immunity is their speciﬁcity to antigenic determinates from
foreign pathogen products to abnormal cellular components such as in cancer. However,
an antibody has the potential to bind to more than one determinate, be it an antigen or
another antibody. These observations led to the idiotype network theory (INT) to explain
immune regulation, which has wax and waned in enthusiasm over the years. A truer mea-
sure of the impact of the INT is in terms of the ideas that now form the mainstay of
immunological research andwhose roots are spawned from the promise of the anti-idiotype
concept. Among the applications of the INT is understanding the structural implications
of the antibody-mediated network that has the potential for innovation in terms of rational
design of reagentswith biological, chemical, and pharmaceutical applications that underlies
concepts of reverse immunology which is highlighted herein.
Keywords: anti-idiotype, carbohydrate mimetic peptides, idiotype network theory, cancer, tumor, mimotopes,
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INTRODUCTION
Scientiﬁc concepts can spring up now and then that captures the
attention of scientiﬁc thought, only to be replaced by new ideas
(Bornholdt et al., 2011). However, some concepts remain latent for
years waiting to be rediscovered. Interestingly, this phenomenon
has been modeled mathematically based on cooperative events in
the evolution of ideas. The modeling suggests that systems with
high innovation rates tend to contain a high degree of noise, along
with many small domains of ideas that are constantly generated
and replaced. In contrast, systems with low innovation rates tend
to have low noise and a state that remains dominant for a long time
until a single event replaces it (Bornholdt et al., 2011). Immunol-
ogy seems to operate on two gears. At the system level, it is of a
low innovation type with just a couple of theories slowly rising
and/or falling over its lifetime of about a century. At the level of
its bordering with molecular biology and cellular physiology, the
avalanche of data spurs a much more intense ﬂow of parallel con-
cepts, e.g., mechanisms of antigen receptor repertoire generation,
cytokine networks, suppression, lymphocyte population structure,
etc. These are concepts that emerge often in loose relationship
to each other as they address different domains of the immune
system. Although of local importance, they often become fash-
ionable and temporarily generalized, attempting to explain more
than they can. This is due, at least in part, to the big theories hav-
ing a hard time catching up because of their slower development.
One such concept is the idiotype network theory (INT) brought
forth by Jerne (1974, 1984). The INT postulates that a popula-
tion of antibodies forms a hierarchical and dynamic network of
interconnected elements that deﬁne the regulation of the immune
system. The promise of the anti-id concept lies in (1) elucidat-
ing the immunological mechanisms associated with the regulation
of the immune response, (2) deﬁning how nature developed its
own approach to reverse engineering which is applicable to vac-
cine design, (3) their use as vaccines and immunotherapeutics,
and (4) their utility in understanding self-tolerance and control of
lymphocyte homeostasis.
THE FOUNDATION OF THE STORY
The basis of the INT is the concept of the idiotype (Id). An Id is a
shared characteristic between a group of B cells (immunoglobu-
lin) or T cell receptor (TCR) molecules based upon the antigen
binding speciﬁcity, and therefore structure of their variable
region. The variable region of TCRs and immunoglobulins con-
tain complementarity-determining regions (CDR) with unique
amino acid structure that determines the antigen speciﬁcity of
the receptor. The structure formed by the CDR is known as the
idiotope. The term Id is often used to describe the collection of
multiple idiotopes, and therefore overall antigen binding capac-
ity, possessed by an antibody. Immunoglobulins or TCRs with a
shared idiotope are the same Id. The antibody Id is determined by
gene rearrangement, junctional diversity, palindromic nucleotides
at sites of single-strand breaks, N-nucleotides, and somatic hyper-
mutations. Inherent to the INT is the relationship between the
combining site (paratope) for antigen and the expression of an Id
(idiotope).
The Network Theory of Jerne postulates that the immune sys-
tem functions as a regulatory network that is comprised of Ids
(Ab1s) and their anti-Ids (Ab2s) inwhichB cells andother antigen-
presenting cells (APC) provide for antigen processing (Figure 1).
The inherent relationships of thenetworkhierarchy activate bothB
andT cells through idiotypic networkdeterminants thatmimic the
three-dimensional structure of the nominal antigen, and thereby
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FIGURE 1 | A model for how conventionalT–B collaboration could
represent a cellular mechanism by which complementary Id+ (Ab1),
anti-Id (Ab2), and anti-anti-Id (Ab3) antibodies communicate in a
T-cell-dependent manner. A central tenet of the network theory is that the
interaction between Id+ and anti-Id immunoglobulin has regulatory
consequences in addition to generating cross-reactive immune responses
to external antigens. The uniﬁcation of these ideas is illustrated as adopted
from a model presented by (Uner and Galvalchin, 2006). An antigenic
determinate X is processed and presented by an antigen-presenting cell
(APC) in association with major histocompatibility complex (MHC) class II
molecules to an antigen-speciﬁc T- helper cell or, in association with class I
MHC, to an antigen-speciﬁc cytotoxic T cell. Signals from theT-helper cell
lead to the activation of B cells that recognize on their own an epitope on X
and produce anti-determinate X reactive antibody (Ab1). Anti-X producing B
cells, as APCs, present peptides of anti-X (idiotypicY peptide) in association
with class II to idiotypeY-reactive or speciﬁc T-helper cell and, in association
with class I, to idiotypeY-speciﬁc cytotoxic T cells. Signals from the
activated idiotypeY- reactive T cells lead to the activation of anti-idiotope
Y-producing B cells (Ab2). Likewise, in this context extracellular Id+
immunoglublin (Ab1) is endocytosed and processed by APC, resulting in
Id-peptides that are presented on MHC Class molecules to Id-speciﬁc
CD4+ T cells. Anti-Y producing B cells, as APCs, present idiotypic Y peptide
in association with Class II to idiotype Z-reactive or speciﬁc T-helper cell
and, in association with Class I, to idiotype Z-speciﬁc cytotoxic T cells.
Signals from the activated idiotype Z-reactive T cells lead to the activation
of anti-idiotope Z-producing B cells (Ab3).
activateAb1 precursors reactivewith foreign or self-antigens. They
may also be responsible for the stimulation and maintenance of
memory T lymphocytes. Thus, MHC-restricted T cells appear to
recognize immunoglobulin by the same rules as those that apply
to recognition of proteins in general. AntibodyAb1, synthesized in
response to a primary antigen, in turn elicits a secondary antibody
Ab2. B cell clones recognizing idiotopes on Ab1 in the generation
of Ab2s are a heterogeneous population displaying multiple speci-
ﬁcities. Sometimes, immunization with Ab2 induces antibodies
(Ab3s), which resembleAb1s as induced by the original or nominal
antigen.
This model suggests that conventional T–B collaboration can
explain communication between complementary Id+ and anti-Id
antibody at the cellular level that integrates present and previous
data on B cell regulation by Id-speciﬁc T cells (Jacobsen et al.,
2010). Ab2 antibodies with antigenic properties have been recog-
nized as two types: one that is the “internal image” binding to the
antigen binding CDR, and another that binds close to the anti-
gen binding Ab1 site. The ﬁrst Ab2 termed by Jerne as Ab2 beta,
the later as Ab2 gamma (Kohler et al., 1989). Ab2 alpha is deﬁned
as an anti-Id without internal imagery to the native antigen. A
fourth kind of anti-Id has been described that binds to a frame-
work region of VH (variable region heavy chain) families (Muller
et al., 1991; Wang et al., 1995). This Ab2 is classiﬁed as Ab2 delta
(Kohler, unpublished data). The role and potential of Ab2 delta
in vaccine development is currently being explored. Ab2 alpha or
Ab2 delta may exhibit a regulatory effect on the production of
antibody bearing the Ab1 Id. Figure 2 shows a ﬂow diagram of
idiotypic interactions and Table 1 lists the different Ab2s.
The INT is perceived tohavehadbetter days and is considered to
be a case in the rise and fall of a scientiﬁc paradigm in today’smain-
stay of immunological research (Eichmann, 2008). What initially
appeared as an exciting new perspective of the immune system is
now viewed as a scientiﬁc vagary, and is perceived to be largely
abandoned (Eichmann, 2008). Literature searches of select key-
words over the last three decades highlight a decline in publications
in the respective topic areas except for anti-Id vaccines (Table 2).
Yet it is this promise that has drawn skepticism, but remains excit-
ing for some because anti-Ids continue to prove their potential
in the clinic (Bhattachary-Chatterjee et al., 2000; Bhattacharya-
Chatterjee et al., 2001;Maruyama et al., 2000; Li et al., 2002; Rufﬁni
et al., 2005; Lee et al., 2007; Neninger et al., 2007; Ai et al., 2009;
Fernandez et al., 2010; Hernandez et al., 2011; Inoges et al., 2011;
Ng et al., 2012).
Perhaps the main weakness of the INT is its claim for gen-
erality while including a very restricted set of components and
interactions in the immune system. With the buildup of data on
its complexity, processes, and properties therein like memory, tol-
erance, and repertoire selection found better explanations in a less
exciting, reductionist context. This made the speculations of the
INT role in these processes at best overstated. Did it lose credibility
altogether? No – only its level of generalization was corrected. So
the “innovation” that brought about the paradigm shift did not
replace the theory in its domain, but rather, expanded the ﬁeld
showing that there is much more to immune mechanisms than
antibodies, B cell clones and their interactions. This is a promise
fulﬁlled.
There are two aspects of the INT that not only survived its
fall but even saw a major development becoming its most sig-
niﬁcant legacy. The ﬁrst, is the role of the network in immune
regulation as an important participant in the assortment of an
improved clinical outcome (Abdeen,2011). This role has been con-
ﬁrmed by the ﬁnding that “auto-anti-idiotypic” antibodies against
the induced antibody (Ab1) arise during the immune response in
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FIGURE 2 |The idiotype cascade. Ab1 binds to anti-idiotypic antibodies in ways associated with Ab2 properties. Ab2δ is a new designation that deﬁnes
binding to framework regions of Ab2 associated with the Ab2 VH family.
Table 1 | Nomenclature of Ab2s.
Anti-Id class Property Reference
Ab2 alpha Non-binding site idiotope Jerne (1974)
Ab2 beta Internal antigen image idiotope Jerne (1974)
Ab2 gamma Near antigen binding site idiotope Kohler et al. (1989)
Ab2 delta Non-binding site, VH-speciﬁc and
outbred shared idiotope
Kohler, unpublished
mice (Kluskens and Kohler, 1974; Cosenza, 1976) and in humans
(Stefanescu et al., 1993). The second, fundamentally proposes
that antibodies can themselves function as surrogates of antigens
and immunogens (McNamara et al., 1984; Hernandez et al., 2008,
2011) that redeﬁnes anti-Ids as network antigens (Kohler et al.,
1989). In short, a promise that has wide sweeping implications is
that anti-Ids can function as mimics of ligands and antigens, func-
tioning as surrogates binding competitively to antigen-speciﬁc cell
receptors. Thus, intrinsically, any antibody can function as a ligand
surrogate by its very nature. This realization deﬁnes anti-receptor
antibodies as surrogate ligands and indicates that this promise of
the INT is still in the mainstream of immunological research but
has morphed into the notion of approaches to targeted therapy
(Goldenberg and Sharkey, 2012).
A major theoretical contribution is also the reassessment of
the role of antibody polyspeciﬁcity. Molecular mimicry is now
ﬁrmly considered as the basis of many autoimmune disorders
where a foreign antigen shares sequence or structural similarities
with self-antigens (Chastain and Miller, 2012; Cusick et al., 2012).
Molecularmimicry in this context has typically been characterized
at an antibody (B cell) or T cell level. Even if an epitope mimic can
support a cross-reactive T or B cell response in vitro, its ability to
induce an autoimmune disease in vivo will depend upon several
factors including the appropriate presentation of the mimicry of
host antigen expressed on the target tissue. In the case of T cell
mimics, the ability to mimic an epitope to induce a proliferative
response depends upon engagement of theMHC-peptide complex
with the TCR (Davies, 1997). However, few investigators truly real-
ize that peptides can be overlapping B cell and T cell epitopes and
or simultaneously involved in the interaction with anti-idiotypic
B and T cells, behaving as a regulatory idiotope (Perez et al., 2002).
On the other hand, the different principles of repertoire selec-
tion makes T- and B-cell antigen receptors independent in their
polyspeciﬁcity (Wucherpfennig et al., 2007) and, generally, only
one of the epitopes will be triggering the process of mimicry but
will recruit the help of the other because of mimicry. Indeed, the
promise of understanding regulation is evident.
Despite that pathogen-associated animal models were often
used to validate vaccination with anti-Ids, anti-Id vaccination
has made it to the clinic for cancer. A number of monoclonal
antibodies that mimic distinct human tumor-associated antigens
as well as Id vaccines have demonstrated encouraging results in
clinical studies for solid tumors (Bhattachary-Chatterjee et al.,
2000; Bhattacharya-Chatterjee et al., 2001; Maruyama et al., 2000;
Rufﬁni et al., 2005; Lee et al., 2007; Neninger et al., 2007; Fernan-
dez et al., 2010; Hernandez et al., 2011; Ng et al., 2012). While
the theoretical hypothesis is sound, trials have been limited and
have not been tested prospectively. Several studies have pro-
vided proof-of-principle of biological efﬁcacy of these vaccine
types, clinical efﬁcacy, and even clinical beneﬁt in small studies
conducted in humans (Bendandi, 2009). However, several ran-
domized clinical trials have failed to achieve their main endpoints
for reasons that might be unrelated to a vaccine (Bendandi, 2009;
de Cerio and Inoges, 2009). While skepticism toward this type
of approach is mounting, better-designed clinical trials might
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Table 2 | Distribution of publications based upon keywords associated with the network theory.
PubMed keyword search [“1980/01/01” (date – publication):
“1990/12/31” (date – publication)]
[“1991/01/01” (date – publication):
“2000/12/31” (date – publication)]
[“2001/01/01” (date – publication):
“2012/8/28” (date – publication)]
Idiotypic network 254 249 105
Idiotypic network theory 32 19 17
Anti-idiotype antibodies 4229 3326 2794
Anti-idiotypes 180 100 29
Anti-idiotypic vaccine 169 268 292
Idiotype 3432 1596 758
Regulatory idiotype 411 65 40
Idiotope 262 158 27
Idiotypy 62 14 2
prove to show efﬁcacy for vaccinations that emphasizes idiotypy
(Bendandi, 2009; de Cerio and Inoges, 2009). Still, the great-
est challenge of immunotherapy by means of antibody-based
vaccines, especially in the context of solid tumor therapy, is to
identify the antibody that will function as a true surrogate-antigen
generating both humoral and cellular immune responses to
tumor cells.
It may seem worth mentioning here a recently debated aspect
of immunoglobulin immunogenicity. The description of immun-
odominant regulatory T cell epitopes in the constant part of
the immunoglobulin molecule (De Groot et al., 2008; Cousens
et al., 2012) seems to add a balancing force to the immuno-
genic variable region with its T and B cell idiotopes. The net
effect, though, should counterbalance the particular idiotopes
not with the self-epitope found on the injected Ab2 molecule
but with the combined amount of the identical constant region
epitopes of the total endogenous immunoglobulin. For that mat-
ter, one can actually argue for a role of (and competition with)
all immunodominant self-epitopes continuously presented. Obvi-
ously, a relatively negligible amount of immunoglobulin injected
as an immunogen would hardly change the repertoire of self-
epitopes presented and the“Tregitope”concept changes nothing in
this case.
BIOLOGICAL VERSUS CHEMICAL MIMICRY
Lately, emphasis is being placed on using neutralizing antibod-
ies as templates to reverse engineer immunogens by working
back to reconstruct the neutralizing epitope by structure-based
design technology with the intent to induce neutralizing anti-
bodies by the mimicking immunogen (Sattentau and McMichael,
2010; Bundle et al., 2012; Lipinski et al., 2012). Id/Anti interac-
tions are nature’s own approach to reverse engineering. Antigen
binding of antibodies is mediated by atomic interactions within
complementary surfaces between antibodies (paratope) and anti-
gens/determinants (epitope). The interaction between antibodies
and antigenic determinants is determined not necessarily by a
primary chemical structure, but by the stereochemistry of the
antigen. Reviews over the years have discussed idiotypic relation-
ships from a structural viewpoint (Kieber-Emmons et al., 1986;
Kieber-Emmons et al., 1987a; Poljak, 1994). In most cases, Ids are
associated, fully or entirely with the CDR of antibodies indicat-
ing that a binding site is both recognizing and being recognized.
Antibodies are known to cross-react with non-structurally related
molecules, and, paradoxically, the distinction between paratope
and idiotope is not straightforward because mimicry is attributed
to the CDRs of Ab2s and requires adjustment for the develop-
ment of a rationale for immunomodulatory approaches using
antibodies as immunogens (Kohler et al., 1989). But why should
this interplay be structurally determined?
One line of evidence that suggests chemical mimicry can reg-
ulate biological mimicry stems from sequence analysis of the
anti-Ids F6 and 4C11, which were deﬁned as anti-Ids for phos-
phorylcholine (PC; Huang et al., 1988). Sequence and structure
analysis suggested that the CDR2 of 4C11 was unique, display-
ing a positive and negative charge distribution that mimics the
charge distribution of the PC head group that deﬁnes a corre-
late with function and structure (Kieber-Emmons et al., 1987b;
Cheng et al., 1988). In fact peptides that mimicked PC were
shown to compete with PC for antigen binding using a reverse
engineering approach (Kieber-Emmons et al., 1987b). The crys-
tal structure of anti-idiotypic monoclonal antibody 409.5.3 and
its idiotypic Fab fragment complex (a feline infectious peritonitis
virus neutralizing antibody) also illustrates the manner in which
two Fabs interact by direct placement of their complementary
CDRs (Ban et al., 1994). Analysis of the Ab1–Ab2 interface reveals
that there is high degree of structural and chemical complemen-
tarity between the two as is observed in other antigen-antibody
complexes.
Superimposed on structural complementarity though is the
idea that antibodies are polyspeciﬁc. Polyspeciﬁcity is a basis for
functional mimicry. Unlike the classical notion in the sense of
a signal, switched from the legitimate target to an inappropriate
self-target, here the context is rather of converging signals com-
ing from a class of ligands carrying a common biological meaning
(Cohn, 2008). For example, a common cross-reactivity between
carbohydrates and intracellular hydrophobic determinants, points
to a possible biological function of carbohydrate/protein mimicry
(unpublished observations). It may overlap structural markers
of dangerous change of the internal environment. Anti-Ids that
mimic carbohydrate antigens are abound in description. The
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premise for antigenic mimicry is thought to rely on the presenta-
tion of reactive groups such as hydroxyl groups that topologically
correspondbetween the antigen and the anti-Id based onhydrogen
bonds, which may or may not be supplemented by hydrophobic
interactions.
Stereochemical similarity may determine an immunochemical
likeness even between molecules belonging to different classes of
compounds, for example, between peptides and polysaccharides
(Luo et al., 2000; Cunto-Amesty et al., 2001a; Monzavi-Karbassi
et al., 2007). Let us consider an antibody and an antigen it is spe-
ciﬁc for. Almost always other structures can be found that bind to
the antibody, competing for the antigen. When such cross-reactive
determinants also induce antibodies cross-reactive with that same
antigen, they are deﬁned operationally as mimics of that same
antigen. This algorithm for deﬁning mimics does not necessitate
complete structural identity between the molecular interfaces in
the antibody/antigen and the antibody/mimic complexes. Further-
more, due to the very nature of mimicry as an instance of antibody
polyspeciﬁcity, it seems intuitively obvious that, in general, differ-
ent mimics bind to the nominal antibody with diverse footprints.
Thus, anti-Ids need not display an exact structural correspon-
dence with the nominal antigen, let alone different stereochemical
aspects fromwhich the same epitope canbe recognized bydifferent
antibodies (Luo et al., 2000; Cunto-Amesty et al., 2001a; James and
Tawﬁk, 2003; Pashov et al., 2005; Monzavi-Karbassi et al., 2007;
Talavera et al., 2009). Although this is the general principle, there
are anecdotal examples of mimicry with a very high structural
ﬁdelity, especially in Id-anti-Id systems, proving that it is not only
possible but also of not too low probability.
STRUCTURAL CHARACTERIZATION OF ANTIBODY
RECOGNITION
The three-dimensional structures of several anti-Id antibodies,
either alone or in complex with an idiotope have been deter-
mined (Garcia et al., 1989; Bentley et al., 1990; Ban et al., 1994,
1996; Evans et al., 1994; Chang et al., 2005). The ﬁrst insight into
the structural aspects of anti-idiotypic antibodies comes fromAb1
(FvD1.3), Ab3 (Fv E5.2) antibodies in the lysozyme system (Fields
et al., 1995; Braden et al., 1996). The study showed that the Id-
anti-Id interaction involves all six CDRs of eachmolecule although
the interaction between E5.2 HCDR1 and D1.3 is achieved only
through bridging water molecules. In the D1.3 complexes with the
lysozymes, the conformation of D1.3 LCDR3 in complexwith E5.2
is dependent on the electrostatic nature of the residue in contact
with the L3 backbone.
The anti-Id antibody mimics the lysozyme by a strong topo-
logical similarity in hydrophilic interactions and by making a
comparable number of Van der Waals contacts to the combining
site of the Ab1. This mimicry is well exempliﬁed by the patterns of
hydrogen bonding: six of the 14 protein–protein interface hydro-
gen bonds in the Ab1-anti-Id Ab2 complex are superimposable
with hydrogen bonds in the Ab1-lysozyme interface, suggesting
ﬁdelity in hydrogen bonding as a basis for cross-reactivity and
mimicry. Not perfect ﬁdelity but close. Interestingly, the sol-
vent structure of the Id-anti-Id antibody complex is observed
to contribute to the mimicry of the lysozyme in the context of
recognition.
The mimicry of E5.2 for lysozyme does not however extend
to the topology of the non-polar surfaces of E5.2 and lysozyme,
which are in contact with D1.3 as revealed by a quantitative
analysis of the contacting surface similarities between E5.2 and
lysozyme. It was concluded that the anti-idiotypic antibody E5.2
mimics lysozyme in its binding interactions with D1.3. Validating
these observations, E5.2, used as an immunogen, induces an anti-
lysozyme response (Fields et al., 1995). This observation underlies
an essential part of the INT; that hydrogen bonding is an impor-
tant element that provides directionality to deﬁning the degree of
ﬁdelity which is often overlooked in deciphering and discussing
the structural basis for mimicry.
SEQUENCE RELATIONSHIPS THAT DEFINE MIMICRY
Bruck et al. (1986) described one of the earliest observations
of shared sequence homology between antibodies and antigens.
Importantly, this system also taught, in a series of papers, how
to develop peptides and small molecules from antibody struc-
ture (Williams et al., 1988, 1989, 1990, 1991; Kieber-Emmons
et al., 1997). Even before the work of Bruck et al., insight as to
the sequence relationships between antigens and antibodies was
emerging (Vasta et al., 1984). To estimate the minimal structural
requirements for cross-reaction of idiotypic determinants, Vasta
et al. (1984) determined the capacity of monoclonal antibodies
speciﬁc for the Id of the PC-binding myeloma protein TEPC-15
for cross-reactivities with the PC-binding, acute-phase protein C-
reactive protein (CRP), and the hemagglutinin from the horseshoe
crab Limulus polyphemus (limulin), which binds sialic acid and
PC. Human CRP displays calcium-dependent binding to a variety
of autologous and extrinsic ligands, and aggregates or precipi-
tates, but which binds with highest afﬁnity to PC residues. Neither
CRP nor limulin showed signiﬁcant overall sequence homology to
vertebrate immunoglobulins.
However,CRP, limulin, andTEPC-15VHshared short stretches
of homology (8–10 amino acids) that mapped to a stretch com-
prised of the CDR2 and third framework region of the TEPC-15
VH. These results suggested either evolutionary convergence
forced upon molecules of diverse evolutionary histories because
of steric requirements of binding the same ligand, or a conser-
vation of primitive combining site gene segments in evolution.
Further studies showed that CRP displays the same idiotope as an
antibody that shares its speciﬁcity for PC (Swanson et al., 1991),
whereby the shared epitope onTEPC15 andCRPwas composed of
similar charged residues. The mechanism by which one molecule
has evolved, or was obtained by chance, similar amino acid
sequences or the homologous three-dimensional crystal structure
of immunodominant epitopes remains a mystery.
B CELL INTERACTIONS
The in vivo and in vitro results involving anti-Ids and PC hapten
suggest that idiotope antigens can function like nominal antigens
to induce antigen-speciﬁc B cell responses, providing a mech-
anistic view for priming and boosting primed B cells (Huang
et al., 1986). The mechanisms of thymic-dependent B cell activa-
tion induced by idiotope and nominal antigen are similar in that
MHC-restricted T and B cells interactions require cognate recog-
nition (Huang et al., 1986). An important take home message was
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suggested that the combined use of idiotope and nominal antigens
in an immunization protocol might provide the maximal protec-
tive immunity. This translates the primary observation embedded
in anti-Id vaccination protocols into the present day use of diver-
siﬁed prime and boost strategies to enhance anti-tumor immunity
(Grosenbach et al., 2001; Monzavi-Karbassi et al., 2003; Nolz and
Harty, 2011).
Mimicry is a powerful concept to develop tools for delineation
of the mechanisms whereby antigens affect lymphocyte function
(Weissberger et al., 1983; Shenk et al., 1984). Antibody speciﬁcity
is determined by a limited number of residues. This fact has
prompted the synthesis of small peptides based onCDR sequences,
which retain binding properties and functions of the intact anti-
body. Studies also suggest that peptides derived from CDRs may
act likewise effectors of the innate and adaptive immune response
opening a new scenario about their interplay with the cellular
immune response (Westerink et al., 1995; Gabrielli et al., 2009).
BecauseB1 cells can strongly activateT cells and induceThelper
type 1 (Th1) cell differentiation in the context of antigen presen-
tation, we have been testing how carbohydrate mimetic peptides
(CMPs) mediate T cell responses. We have shown that immuniza-
tion of mice with a CMP reactive with anti-GD2antibodies (GD2
is a tumor antigen expressed typically on cells of neuronal origin),
induce GD2 reactive IgM antibodies (Wondimu et al., 2008). This
CMP also induces a DTH response to GD2-positive D142.34 cells,
while no response was observed against the GD2-negative express-
ing cell line B78.H1. The anti-GD2 IgM induced by CMP plays the
role of an initiating factor for a DTH response perpetuated by
T cells cross-reactive with CMP and an unknown antigen on the
tumor cells line, which have been stimulated during the prim-
ing with CMP. This observation suggest that the dual character
of a CMP carrying a T cell epitope but also mimicking unre-
lated carbohydrate epitope, provides for long-term IgM responses
by promoting other aspects of cooperation between particular
B cell subpopulations and CMP-speciﬁc T cells (Cunto-Amesty
et al., 2003).
We further demonstrated that CMPs direct the generation of
tumor-associated carbohydrate antigens (TACA) reactive antibod-
ies in immune deﬁcient Xid mice that generally fail to respond to
T independent antigens (Cunto-Amesty et al., 2001c). Depend-
ing on formulation, CMPs can target repertoire compartments
inaccessible to native TACA in these mice. Therefore, we hypoth-
esize that CMPs, peptides derived from anti-Id CDRs and anti-Ids
can stimulate B cell compartments and activate effector cells that
bridge innate and adaptive immunity (Pashov et al., 2010).
TARGETING B CELL IDIOTYPES AS A SPECIAL CASE
B cell malignancy is usually derived from a single expanded B
cell clone, which expresses an immunoglobulin with a unique Id
(Shaffer et al., 2002). Therefore, anti-B cell antibodies targeting
Ids are especially useful to probe the biology of B cell malig-
nancies. The use of anti-B cell antibodies targeting Ids is also a
model for therapeutic modality targeting receptors because the
expression and signaling of the membrane bound immunoglob-
ulin constituting the B cell receptor (BCR) is critical for cell
survival andproliferation (Choi andKipps,2012; Kenkre andKahl,
2012). Anti-Ids function as anti-receptor antibodies in this case
whereby they directly recognize the tumor-associated Id (anti-
gen) to mediate both antibody-dependent cellular cytotoxicity
and signaling-induced cell death (Tutt et al., 1998). Lymphoma
has been the model for the clinical utility of “anti-Id” therapy
(Hsu et al., 1997; Rufﬁni et al., 2002), serving as a tumor-speciﬁc
antigen for therapeutic vaccine development. Immunization of
lymphoma patients with their own tumors generates humoral and
cellular immune responses to their lymphomas (Neelapu et al.,
2006). However, the clinical impact of an Id directed immune
response is still under evaluation (Mahaseth et al., 2011) and often
reviewed (Bendandi, 2009; Brody et al., 2011; Inoges et al., 2011;
Hollander, 2012).
Structurally, tumor-speciﬁc Id might be considered in the con-
text of a privileged target for vaccine therapy. The main goal of
any biological therapy of tumors is the selectivity of the agent
used with immunotherapy representing the protypical approach.
In the case of lymphoma, the tumor-speciﬁc antigen is the unique
variable region of the immunoglobulin produced by the malig-
nant clone and anti-Ids use is based on their ability to detect
highly restricted or “private” Ids therein. “Private” Ids are spec-
ulated to be associated with CDR regions while so-called “public”
Ids might be related to framework residues. Such “private” Ids
are reﬂected in somatic mutation, which might be relatively
unique to an individual. Consequently, a major obstacle in pro-
duction of Id vaccines derives from its patient-speciﬁc nature
that requires the generation of a custom-made product. Anti-
Id/Id interactions are also known to be mediated by framework
residues (Brown et al., 1991), suggesting that framework residues
affect Id expression (Corti et al., 1994) as originally proposed
(Kieber-Emmons andKohler, 1986; Kieber-Emmons et al., 1987a).
However, because the focus is on developing both humoral and
cellular immune responses to B cell Ids, CDRs are more likely tar-
gets for T cells. T cell lines generated from lymphoma patients
actively immunized with Id protein were shown to speciﬁcally
recognize CDR-derived peptides (Baskar et al., 2004). Synthetic
peptides corresponding to hypervariable regions of immunoglob-
ulin heavy chain have been described to be speciﬁcally stim-
ulated by CD4+ and CD8+ T cells to proliferate and secrete
proinﬂammatory cytokines in an MHC-associated manner
(Baskar et al., 2004).
However, the plasticity of the BCR repertoire and the structural
similarities among BCR and TCR allow antibodies to effectively
mimic TCR binding to MHC (Polakova et al., 2000). Because a
large number of HLA-binding idiotypic peptides can be identi-
ﬁed among antibody hypervariable sequences, such peptides may
spontaneously induce a type I MHC class I- as well as class II-
restricted memory T cell response (Hansson et al., 2003). Early
studies suggested that antigen-binding receptors onT lymphocytes
and IgGantibodieswith the sameantigen-binding speciﬁcity as the
TCRs display shared or identical Ids (Binz andWigzell, 1975). Such
shared Id might be associated with framework residues. While
some reports associate CTL responses to framework residues
(Trojan et al., 2000; Gricks and Gribben, 2003) framework pep-
tides might play a more fundamental role in regulation in which
Tregs induced by a shared Id epitope can systemically suppress T
cell responses against Id-derived and immunodominant foreign
epitopes in vivo (Warncke et al., 2011).
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T CELL INTERACTIONS
In addition to inducing antibodies, Ids/anti-Ids also induce cel-
lular responses. Such studies suggest that T cells need to be
integrated into idiotypic regulation (Jacobsen et al., 2010). The
ability to primeT cells derived fromnormalHLA-matched donors,
rather than patients, may have direct application to current strate-
gies, designed to generate allogeneic tumor-speciﬁc T cells for
adoptive transfer (Weng et al., 2011a,b). MHC-restricted T cells
appear to recognize immunoglobulins by the same rules as those
that apply to recognition of proteins in general (Eyerman et al.,
1996). In this context it is easy to rationalize that an Id+ B cell
presents Id peptides to Id-speciﬁc T cells. It follows that an Id+
B cell primarily will be regulated by a limited set of T cells spe-
ciﬁc for highly expressed germ-line (maybe) Id− and to a lesser
extent by a diverse set of T cells speciﬁc for a multitude of Id-
peptides derived from somatically mutated (maybe) anti-Id Ab.
As for the anti-Id B cell, the converse is expected to hold true.
Thus, complementary Id+ B cells and anti-Id B cells are antici-
pated to be regulated by partly overlapping sets of Id-speciﬁc T
cells whose Id-peptide/MHC class II ligands are expressed to dif-
ferent levels by the two complementary B cells (Jacobsen et al.,
2010). More importantly, observations that T cells are activated
by Id peptides associated within the CDRs imply that T and B
cell epitopes do overlap and such peptides function as regula-
tory (Perez et al., 2002). Id-speciﬁc T cell clones can recognize
and respond to idiotypic determinants on B cells (Eyerman et al.,
1996; Osterroth et al., 2000;Wen et al., 2001). Id-reactive T cells are
MHC-restricted and recognize idiotypic determinants in the form
of peptide fragments in the context of MHC class II molecules
presented on APCs. This type of binding suggests that a confor-
mational Id was processed and presented to T cells in a manner
that maintained its structure. It is known for sometime that the
overlapping topology of T and B cell epitopes within synthetic
peptides does not necessarily impair B cell immunogenicity
(Harris et al., 1996).
In terms of autoimmunity, molecular mimicry is deﬁned as the
theoretical possibility that sequence similarities between foreign
and self-peptides are sufﬁcient to result in the cross-activation
of autoreactive T and B cells (Ang et al., 2004). Apart from Ab2s
inducing antibodies, there is evidence for differences among the
Ab1-Ab2-Ab3 cascade induced by protective and non-protective
anti-Id attributed to cellular responses (Raychaudhuri et al., 1990).
Among various anti-Ids typed serologically as an internal image
Ab2 of the mouse mammary tumor virus tumor-associated anti-
gen gp52, only one induced protective immunity and was effective
in immunotherapy. The DNA sequence of the variable regions
of six anti-Ids was determined. Search for amino acid sequence
homologies between the Ab2s and gp52 showed the strongest
similarities in sequence in the CDR2 of the light chain for the
protective Ab2 with a T cell epitope on gp52. This ﬁnding was the
ﬁrst to raise the question of where the short peptides, which carry
T cell-deﬁned epitopes, are located and their relationship with the
tumor antigen.
In more recent studies, Ab2s with known amino acid sequence
displayed similarity with peptides from a corresponding tumor
antigen (carcinoembryonic antigen, CD55, and human high
molecular weight melanoma-associated antigen), but differed
from the tumor antigen peptides by the presence of side chains
known to mediate stronger binding with MHC (Spendlove et al.,
2000; Kawano et al., 2005; Ullenhag et al., 2008). In particu-
lar in the CD55 system amino acid homology was identiﬁed
between three CDRs of the anti-id and three regions of CD55
(Spendlove et al., 2000). Anti-anti-idiotypic (Ab3) polyclonal anti-
bodies raised against the Ab2 showed speciﬁc binding to these
peptides. The antibodies were also found to bind synergistically to
combinations of these peptides, indicating cooperatively between
the peptides in stabilizing antibody binding (Spendlove et al.,
2000). These ﬁndings contribute to identifying the mechanism
by which a human anti-idiotypic antibody is able to mimic a
tumor-associated antigen and stimulate anti-tumor B and T cell
responses.
A more direct approach is proposed to use anti-Ids and
monoclonals to target antigens directly to APC (Durrant et al.,
2011). One approach entering the clinic stimulates anti-tumor
immunity using monoclonals genetically engineered to express
tumor-speciﬁc T cell epitopes to enhance T cell activation to erad-
icate tumors (Durrant et al., 2011). This work is an off-shoot
of early ideas on antigenizing antibodies (Zanetti, 1992). How-
ever, natural regulatory T cells might control the speciﬁcity of
T cell-mediated anti-Id immunity (Warncke et al., 2011). Tregs
induced by a shared Id epitope can systemically suppress T cell
responses against Id-derived and immunodominant foreign epi-
topes in vivo (Warncke et al., 2011). Collectively, these results
further highlight the promiscuity of peptide sequences were a sin-
gle antibody or TCR can be activated by a few crucial residues
(Polakova et al., 2000). Consequently, again choosing the correct
anti-Id is a challenge.
STRUCTURAL CONSIDERATIONS IN THE DESIGN OF MIMICS
In 1986, we suggested that the ultimate goal for Id vaccines was to
prepare peptide vaccines derived from idiotypic sequence regions
mimicking antigenic structures (Kieber-Emmons et al., 1986). We
have accomplished this in an infectious model, being the ﬁrst to do
so (Westerink et al., 1995) anddeﬁnedmanyof theparadigms asso-
ciated with using such peptides (Cunto-Amesty et al., 2001b). We
have applied lessons learned from the network theory to develop
peptides that mimic TACA (Monzavi-Karbassi et al., 2007), bring-
ing one of them into the clinic in a phase I safety study in breast
cancer subjects (Monzavi-Karbassi et al., 2007) and now moving
into a phase II trial of high risk breast cancer subjects to prevent
recurrence of breast cancer.
Much like anti-Ids, peptide mimics may elicit anti-poly-
saccharide responses, but fail to elicit the Ids and isotypes observed
in the protective response to the microbial antigen (Harris et al.,
2002). Functional antibodies depend not only on the host’s ability
to mount an immune response, but also on its ability to mount the
correct immune response. Whether an antibody response is pro-
tective or not depends on both the ﬁne antigenic speciﬁcity that
may be associated with particular Ids and epitope binding charac-
teristics, and the isotype, determining antibody effector function.
And herein lies the problem with mimics; the immune response is
only assayed after a choice is made as to which mimic is to be fol-
lowed. So what lessons can be learned about choosing the correct
mimic?
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In the ﬁrst instance, the judicious choice of peptides for testing
antibody responses against should be based on the peptide inter-
action with both the heavy and light chain in order to induce
antibodies with similar antigen-speciﬁc properties (Luo et al.,
2000); as the combination of heavy and light chains will inﬂu-
ence speciﬁcity (Kabat and Wu, 1991). Thus, both the variable
and the constant region of the antibodies induced by a peptide
mimic or mimotope must be considered when assessing the suc-
cess of any immunization. One way to determine this is to use
structural information of the antibody–antigen interactions, e.g.,
reverse engineering concepts.
FIDELITY OF MIMICRY
We have previously reviewed the structural concepts and
approaches used in vaccine design applications that illustrate the
value and limitations of using chemical (peptide libraries which
are mimics of a ligand) and immunological information to deﬁne
novel peptide immunogens that function as mimotopes to gener-
ate immune responses targeting TACA (Pashov et al., 2005) and
glycans on the human immunodeﬁciency virus (Pashov et al.,
2007). In this context we showed early on that concepts associated
with pharmacophore design (now considered reverse engineer-
ing) could be used to deﬁne CMPs applied to vaccine design
(Luo et al., 2000; Cunto-Amesty et al., 2001a). We demonstrated
that a structure-assisted vaccine design approach, whereby small
molecules, deﬁned in crystallographic databases, could be used
to theoretically deﬁne peptide mimetics emulating the three-
dimensional interaction scheme of a native carbohydrate antigen
(Luo et al., 2000; Cunto-Amesty et al., 2001a). More importantly
it was shown that virtual screening led to motifs being observed
experimentally (Luo et al., 2000).We have also shown that by using
this approach, an immunogenic peptide can be designed de novo
(Cunto-Amesty et al., 2001a) and have shown that CMPs reac-
tive with lectins and antibodies can induce antibodies with the
same functionality as lectins and antibodies (Monzavi-Karbassi
et al., 2005).
To generate sustained immunity to TACAs, we have developed
immunogens based on CMPs – a strategy whose clinical promise
is supported by our preclinical studies (Monzavi-Karbassi et al.,
2007). CMPs can induce anti-tumor cellular responses, includ-
ing CMP- and TACA-reactive Th1 CD4+, and tumor-speciﬁc
CD8+ cells that may compensate for low-titer humoral responses
(Monzavi-Karbassi et al., 2001, 2004). Most of all, unlike TACAs,
CMPs can prime for memory responses to TACAs (Monzavi-
Karbassi et al., 2003), suggesting that the CMPs facilitate cognate
interactions between B cells and T cells, which is something that
TACAs do not facilitate, but anti-idiotypic antibodies and peptides
should and can do.
The question remains of how to enhance the ability of TACA
mimetic peptides to induce TACA-speciﬁc antibodies with higher
titers and association constants. We tested the hypothesis that
improving the hydrogen bond pattern through amino acid substi-
tutions in a CMP, to be coincident with that for the carbohydrate
ligand, will enhance the ability of CMPs to elicit anti-TACA
antibodies with high titers and association constants. Based on
anti-Id/Id crystal structures, highly directional bonds represent
an important set of interactions to establish a basis for mimicry
because theymainly confer the speciﬁcity in binding of the peptide
and the carbohydrate antigen.
MIMICS FOR GD2 ANTIGEN
In previous studies, we made use of the crystal structure of
the Fab fragment of ME36.1 has been determined (Pichla et al.,
1997), showing that its CDRs form a groove-shaped binding site.
Molecular modeling has placed a four-residue sugar, represen-
tative of GD2, in the antigen-binding site showing much of the
interaction with GD2 contributed by heavy chain interaction.
Based upon hydrogen bonding schemes with the GD2 antigen, we
used conformational and energy analysis to deﬁne potential bind-
ing modes of a CMP in the crystallographically deﬁned ME36.1
binding pocket (Monzavi-Karbassi et al., 2007). Molecular mod-
eling of the CMP in the ME36.1 binding site indicates that the
CMP only shared two hydrogen bonds with the GD2 antigen
when binding to ME36.1. This is in contrast to the seven hydro-
gen bonds formed between GD2 and the monoclonal antibody
ME36.1.
Based upon hydrogen bonding schemes with the GD2 anti-
gen, we wanted to determine if we could modify this CMP to
increase the level of GD2 antigenic mimicry. Based upon confor-
mational studieswe surmised that removing the ﬁrst three residues
of the CMP would result in a peptide with a binding mode with
ME36.1 with an increased number of hydrogen bonds in common
with the way theGD2 antigen binds toME36.1 (Monzavi-Karbassi
et al., 2007). The redesigned CMP shared ﬁve hydrogen bonds in
common with GD2 in binding to ME36.1. Computer-based bind-
ing studies indicate that the topographical binding mode of this
redesigned CMP overlaps that of GD2 in the ME36.1 combining
site. Our studies indicate that the redesigned peptide represents
a more faithful mimic of ganglioside binding the monoclonal
antibody ME36.1 than its original homolog based upon hydrogen
bonding of ME36.1 to GD2. Immunization with this redesigned
peptide resulted in enhanced antibody responses to GD2 and to
tumor cells expressing GD2.
Although structural analysis may raise the conﬁdence that the
isolated peptide will have functional value, the induction of cross-
reactive immune responses remains the ultimate proof of mimicry.
To test if the increase in the level of GD2 mimicry translates
into an improved GD2 reactive response, mice were immunized
twice with versions of the CMP peptide (P10 original: GVVWRY-
TAPVHLGDG; P10s WRYTAPVHLGDG; synthesized as MAPs)
and then bled 7 days after the boost (Monzavi-Karbassi et al.,
2007). Immunization with MAP-P10s induced serum IgM anti-
bodies superior in GD2 binding than serum antibodies induced
by P10 (Monzavi-Karbassi et al., 2007). Serum IgM antibodies
were also more reactive with the GD2-positive human WM793
cells, suggesting that an improved level of GD2 mimicry lends to
an improved antibody response against GD2 (Monzavi-Karbassi
et al., 2007). These results validated the hypothesis that mimetics
canbemore faithful in theirmimickingpotential. Such results con-
ﬁrm that stereochemically peptides and carbohydrates can bind
to the same antibody-binding site, and that peptides can struc-
turally mimic salient features of carbohydrate epitopes binding to
a receptor fulﬁlling a promise of the anti-Id concept with these
CMPs being tested in phase I trials.
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SUMMARY
The regulation of immune responses is still in the mainstream of
immunology research. However, the paradox of today’s immunol-
ogy is the lack of correspondence between the progress in basic
science and the success of clinical applications. Many clinical trials
in cancer currently ongoing aim to either stimulate an anti-tumor
immune response or thwart immune suppression. Among those
clinical applications are immunotherapeutics that make use of
antibodies in some way. Moreover, antibodies and B cells are still
considered beyond their effector roles, in terms of regulation and
control of the mechanisms of tolerance.
Far from being refuted, concepts derived from INT have the
potential to fuel new ideas and therapeutic approaches. Recent
studies, reviewed here, conﬁrm that idiotypy concepts hold
promise in several aspects. First, although the basic immune phe-
nomena are nowknown tohave their origins in complexmolecular
and cellular interactions, idiotypic control exists and has undoubt-
edly its place in the overall immune dynamics, especially in
selection of the antigen receptor repertoires. Second, studying
idiotypic phenomena unveiled a mechanism of immune system’s
natural “reverse engineering” of antigens. A stimulating exercise
in system immunology, INT provides also intellectual tools to
understand how the immune system preserves structural infor-
mation. Third, as an ultimate proof of validity, these concepts
of decoupling of structural information from its carrier lead to
applications in the development of vaccines and immunother-
apeutics. Finally, INT helps understand the difference between
molecular interactions of variable speciﬁcity and immune recog-
nition as a function of the entire system. Thus, it contributes to
the construction of an essential immunological paradigm.
On the one hand, the INT tackles the idea that immunoglob-
ulin/immunoglobulin recognition mechanisms play a role in
self-tolerance and control lymphocyte homeostasis. Although we
know now that this is not the main mechanism of tolerance,
signals, generated in the process, clearly control lymphocyte dif-
ferentiation and homeostasis. Idiotypic interactions are known to
participate in B cell repertoire selection, at least early in life and in
restricted B cell compartments (Elliott and Kearney, 1992; Diet-
rich et al., 1993), contributing to dominant self-tolerance. On the
other hand, the INT deﬁnes a paradigm of surrogate ligands and
by extension –mimic-based immunogens. In principle, the level of
innovation in INT is actually high, spawning some“high turnover”
ideas and some others that form the mainstay of immunological
research.
The INT might have been too innovative. Probably it came too
much ahead of its time, followed by a heap of new data on struc-
tures and mechanisms in immunology that greatly expanded our
view. The latter served for a kind of reductionist revenge instead
of reassessment and development of the idea (except for isolated
attempts, e.g., Varela and Coutinho, 1991). The skepticism in INT
utility, that thus ensued,was the largest factor in its rise and fall. An
interesting example is the perceived role of diverse T cell subpop-
ulations in anti-cancer responses – a major shift of the emphasis,
despite monoclonal antibodies being at the front line of some
cancer therapies. Perhaps antibodies have not failed, but we do
not know how to appropriately apply them and have not fully
grasped the lessons learned from them. That very skepticism in
INT is to blame, at least, to some extent for this situation. More
importantly, only few appreciated the role of mimicry of antibod-
ies in forming the idiotypic network (Varela and Coutinho, 1991;
Coutinho, 1995). This may have contributed also to the premature
fall of this beautifully speculative concept. Not unlike suppressor T
cells which came back as Tregs, we anticipate that the rising inter-
est in systems biology sooner or later will lead to a reassessment
of the role of antigen repertoire networks at the systems biology
level.
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